-- Pharmaceutical company Lupin (NSE:LUPIN, BOM:500257) has launched Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States, according to a Wednesday filing to the Indian stock exchanges.
The company launched the drug following the approval from the U.S. Food and Drug Administration as bioequivalent to AstraZeneca AB's Xigduo XR.
The company's shares were down nearly 1% in recent trade.